Agilent Technologies Announces Expanded License Agreement With Incyte Genomics to Enable Production of Both cDNA- and Oligonucleotide-Based Gene Expression Microarrays.Business Editors/Medical Writers PALO ALTO Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif.--(BUSINESS WIRE)--Sept. 17, 2001 Agilent Technologies This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. Inc. (NYSE NYSE See: New York Stock Exchange :A) and Incyte Genomics Inc. (Nasdaq:INCY), the leading genomic information company, today announced an expanded licensing agreement to further Agilent's development and commercialization of gene expression microarrays using Incyte's gene patent portfolio and genomic databases. Through this license agreement with Incyte, Agilent will now be offering a more comprehensive range of catalog catalog, descriptive list, on cards or in a book, of the contents of a library. Assurbanipal's library at Nineveh was cataloged on shelves of slate. The first known subject catalog was compiled by Callimachus at the Alexandrian Library in the 3d cent. B.C. and custom microarrays for gene expression research. Agilent, using Incyte's LifeSeq(R) database and gene patent portfolio, will develop highly specific cDNA- and oligonucleotide-based microarrays for detecting and monitoring gene expression. Gene expression microarrays are used for the identification of critical genes involved in various biological processes. In addition, this agreement will enhance the development of custom arrays for those customers who are part of Agilent's Technology Access Program and are either subscribers to Incyte's databases or wish to include LifeSeq sequences or Incyte-patented sequences in their custom arrays. Incyte will receive additional license fees in addition to royalties on sales of Agilent microarrays developed using Incyte's patent portfolio and technology. "We are pleased to be working with Incyte to further the solutions available to customers working in drug discovery and bioagriculture research," said Bill Buffington, vice president and general manager of Agilent's Life Sciences Business Unit. "Incyte's expansive gene patent portfolio and premier sequence information databases are strong complements to Agilent's ability to design and deliver custom and catalog microarray See micro array. microarray - A technique for performing many DNA experiments in parallel. Nothing to do with computers. solutions." "Through this agreement, Agilent will now have one of the most comprehensive microarray product lines available," said Roy A. Whitfield, chief executive officer of Incyte. "This should enhance Agilent's ability to capture a significant portion of the microarray market recently estimated by Frost and Sullivan to be approximately $2.6 billion by 2004/a. In addition, the product line expansion will benefit Incyte through greater licensing and potential royalty revenues and by increasing the demand for our databases among Agilent array customers." With these arrays, researchers will be able to characterize expression of many thousands of genes at one time and identify gene activity during important biological processes, such as during disease progression and pathology, human growth and development, and in response to drugs or toxins. About Incyte Genomics, Inc. Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. patents covering human full-length genes and the proteins they encode (1) To assign a code to represent data, such as a parts code. Contrast with decode. (2) To convert from one format or signal to another. See codec and D/A converter. (3) The term is sometimes erroneously used for "encrypt. and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's Web site at http://www.incyte.com. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global technology leader in communications, electronics and life sciences. The company's 43,000 employees serve customers in more than 120 countries. Agilent had net revenue of $9.4 billion in fiscal year 2000, as restated to reflect the sale of its healthcare business. Information about Agilent is available on the Web at www.agilent.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to Incyte's ability to obtain potential revenues received on royalties Synopsis On Royalty: A Very Polite Inquiry into Some Strangely Related Families is the attempt of Jeremy Paxman to examine and understand how the increasingly irrelevant institution that is Monarchy has managed to continue to hold to the imaginations of the public. from sales of microarrays, are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, the ability to meet goals of the collaboration; Incyte's ability to enforce drug target patents and changes in laws as they affect such patents; alternative technological advances and competition; and other risks detailed from time to time in Incyte's SEC reports, including their respective Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. for the Incyte quarter ended June 30, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements. This news release contains forward-looking statements (including, without limitation, statements relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc Agilent's ability to offer a more comprehensive range of catalog and custom microarrays for gene expression research; to develop custom arrays for those customers who are part of Agilent's Technology Access Program and are either subscribers to Incyte's databases or wish to include LifeSeq sequences or Incyte-patented sequences in their custom arrays; the success of Agilent's use of Incyte's LifeSeq database and gene patent portfolio to develop highly specific oligonucleotide-based microarrays for detecting and monitoring gene expression; and to provide one of the most comprehensive microarray product lines available)) that involve risks and uncertainties that could cause results of Agilent Technologies to differ materially from management's current expectations. These risks are detailed in Agilent's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended Oct. 31, 2000, Quarterly Report on Form 10-Q for the quarter ended April 30, 2001, and Current Reports on Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. filed June 29, 2001, Aug. 15, 2001 and Aug. 22, 2001. /a Source: "World Biochip biochip Small-scale device, analogous to an integrated circuit, constructed of or used to analyze organic molecules associated with living organisms. One type of theoretical biochip is a small device constructed of large organic molecules, such as proteins, and capable of Market Report," Frost & Sullivan, March 2001. LifeSeq database is a product of Incyte Genomics, Inc. NOTE: Press releases, photography and other information can be accessed and downloaded from the Agilent Technologies Life Sciences and Chemical Analysis newsrooms at www.agilent.com/about/newsroom/lifesciences/ and www.agilent.com/about/newsroom/chemical/. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion